The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.
Go to Source
https://medicalxpress.com/rss-feed/
Go to Source
https://medicalxpress.com/rss-feed/